Oncology Technology Center: CAR-T Transfer for Hospitals and Health Systems
Prepared by: CancerCareE B2B Team · Updated: June 2026 · Type: Partner program description
CancerCareE acts as an information intermediary between hospitals and health systems on one side, and manufacturers of biotechnology equipment and CAR-T solutions on the other. We do not sell training, equipment, or licenses directly: all technical services are provided by partner biotechnology companies. Our role is to help establish contact and navigate the options.
CAR-T Technology Transfer Program
We do not connect patients with treatment — we help hospitals and health systems establish contact with partner biotechnology companies that provide comprehensive solutions for CAR-T cell therapy manufacturing.
🧬 Production Kits
Complete CAR-T production kits from partner manufacturers: viral vectors (CD19, CD22, BCMA), closed-loop bioreactors, and quality control reagents.
👨🔬 Training and Certification
Training programs for medical and technical personnel are provided by partner biotechnology companies. CancerCareE does not conduct training itself — we help arrange contact.
🏗️ Equipment and Infrastructure
Installation of cleanrooms, apheresis machines, flow cytometers, and cryopreservation systems — through partner suppliers. Turnkey solutions.
Technology Transfer Process
Opportunity Assessment
The partner company assesses your hospital's infrastructure, regulatory environment, and clinical capabilities. Initial consultation — via CancerCareE.
Custom Solution Development
Customized technology package: target antigens (CD19, BCMA, etc.), scale (clinical vs. commercial), and budget — from the partner company.
Training and Certification
3–6-month training program for your team — delivered by the partner biotechnology company. CancerCareE coordinates communication.
Equipment Installation and Validation
Equipment installation, IQ/OQ/PQ validation, cleanroom certification — by the partner company and its subcontractors.
Ongoing Support
Technical support, reagent supply chain management, quality monitoring — from the partner company.
Investment Overview
| Component | Basic Package | Advanced Package | Commercial Scale |
|---|---|---|---|
| Target Antigens | CD19 only | CD19 + BCMA | CD19, CD22, BCMA + custom |
| Annual Capacity | 50 patients | 200 patients | 1000+ patients |
| Equipment | Basic cleanroom + manual systems | ISO 7 + semi-automatic | ISO 5 + fully automatic |
| Training Duration | 3 months | 6 months | 12 months + ongoing |
| Investment Range | $2M – $5M | $8M – $15M | $20M – $50M |
| Payback Period | 3–5 years | 2–4 years | 1–3 years |
CAR-T Manufacturing Kits and Components
Everything needed to build a modern CAR-T production facility — supplied by partner manufacturers.
🦠 Viral Vectors
GMP-grade lentiviral and retroviral vectors for CAR gene delivery.
⚙️ Closed-Loop Bioreactors
Automated cell culture systems that minimize contamination risk.
- Disposable cassettes
- Real-time monitoring (pH, DO, glucose)
- Scalable from 50 ml to 2 L
- FDA/EMA compliant
🔬 Quality Control Systems
QC reagents and instruments for product safety, purity, and potency.
- Flow cytometry panels
- Endotoxin testing kits
- Mycoplasma detection
- Potency assays
❄️ Cryopreservation and Storage
Long-term cell storage solutions with validated freezing protocols.
- Controlled-rate freezers
- Liquid nitrogen storage (−196°C)
- 24/7 temperature monitoring
- Backup power systems
Other Advanced Oncology Technologies
Beyond CAR-T: an overview of technologies available through partner companies.
🤖 AI Imaging
Deep learning algorithms for earlier cancer detection.
🩸 Liquid Biopsy
Detection of 50+ cancer types from a single blood test.
🦾 Robotic Surgery
Minimally invasive systems with sub-millimeter precision.
💉 mRNA Therapy
Personalized cancer vaccines targeting neoantigens.
✂️ CRISPR Editing
Precise genome editing for next-generation CAR-T.
🔬 Smart Nanomedicine
Nanoparticle delivery systems targeting tumors.
Technology Readiness Assessment
Is your hospital ready for CAR-T technology transfer? Answer the questions for a preliminary assessment — a partner company will review your request.
🔒 Confidential. Reviewed by the partner technology transfer team within 48 hours.
Technology Transfer Success Stories
Large University Hospital → First CAR-T Center in the Region
National Health System → Multi-Center CAR-T Network
Frequently Asked Questions
❓ How long does it take to establish CAR-T production?
Answer: A typical timeline is 12–24 months from contract signing to treating the first patient. This includes opportunity assessment (1 month), design and construction (6–12 months), equipment installation and validation (3–6 months), staff training (3–6 months), and regulatory approval (varies by country).
❓ Is prior cell therapy experience required?
Answer: No. The program is designed for institutions starting from scratch. The partner company provides comprehensive training for all personnel. A hematology/oncology department is recommended.
❓ What regulatory approvals are needed?
Answer: Requirements vary by country. The partner company provides regulatory support: licensing, GMP certification, clinical trial applications, and product registration. Experience with FDA, EMA, NMPA (China), and other agencies.
❓ Can the technology package be customized?
Answer: Yes. Each package is tailored to your institution's needs: target antigens, production scale, automation level, and equipment brands. Development of custom CAR constructs is also supported.
Ready to discuss CAR-T transfer for your institution?
Hospital, research center, or national health system — we will help you establish contact with partner biotechnology companies.
Request a Transfer Proposal